Avi Ben-Abraham

Avi Ben-Abraham is an Israeli-American scientist who was involved in research in the fields of low temperature medicine, cryonics, and human and stem cell cloning.

Work

An active promoter of cryonics, Ben-Abraham was the chairman of the American Cryonics Society.

Business Ventures

Dr. Ben-Abraham is the founder, former chairman and chief executive officer of Ben-Abraham Technologies Inc. (now ANI Pharmaceuticals Inc.- NASDAQ : ANIP), an American biotechnology company. He was tasked with overseeing the development of calcium phosphate nanotechnology (CaP) for vaccine adjuvants and delivery technology for biodefense vaccines. The company signed a CRADA with the U.S. Army for the development of non-injected biodefense vaccines against anthrax, ricin and staph.

Politics

In 1999, Ben-Abraham was endorsed by Israel's Prime Minister Benjamin Netanyahu, and won the primaries for a top seat on the governing Likud party list of candidates for the Knesset,.[1][2] He was ultimately not elected as both the Likud party and Netanyahu were defeated by Labor party leader, former Israeli Defense Forces chief of staff Lt. General Ehud Barak.

Human Cloning

In 2001 Ben-Abraham, along with Panayiotis Zavos, a reproductive physiologist, and Severino Antinori, an infertility specialist, announced their attempt at cloning the first human[3] in an undisclosed country by 2003. The group attempted the procedure, but stated that it was unsuccessful.[4]

References

  1. ↑ http://www.metroactive.com/papers/metro/05.13.99/public-eye-9919.html
  2. ↑ "Archived copy". Archived from the original on 2001-04-18. Retrieved 2001-04-18.
  3. ↑ Bonnicksen, Andrea (2002). Crafting a Cloning Policy: From Dolly to Stem Cells. Washington, D.C.: Georgetown University Press. p. 220. ISBN 9781589018082.
  4. ↑ Morgan, Rose (2005). The Genetics Revolution: History, Fears, and Future of a Life-Altering Science. Westport, Connecticut: Greenwood Publishing Group. p. 219. ISBN 0313336725.
This article is issued from Wikipedia - version of the 10/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.